By Steve Goldstein, MarketWatch

The extent of stockpiling ahead of a possible hard Brexit was on display in Tuesday in areas ranging from manufacturing data to a bakery's results.

U.K. manufacturing PMI rose to a four-month high in September -- but driven by stockpiling, IHS Markit said.

Levels of output, new orders, new export business and employment fell while those for stocks or purchases and input buying volumes rose, IHS Markit said as the headline index rose to 48.3 in September from 47.4 in August.

Baker Greggs (GRG.LN) meanwhile said it was preparing for the potential impact of the U.K.'s departure from the European Union "by building stocks of key ingredients and equipment that could be affected by disruption to the flow of goods into the U.K." The company said it's seeing pressure on both labor and food input costs.

Greggs said it was reiterating its full-year forecast as same-store sales in the 13 weeks to Sept. 28 rose 7.4%, which is slower than the 9.4% growth in the nine months to Sept. 28. "This was inevitable at some point, and whilst the company's guidance remains unchanged, this may encourage (remaining) momentum investors to look elsewhere," said analysts at Barclays of the slowing sales growth.

Greggs shares tumbled 6.4%.

   The FTSE 100   more broadly declined 0.12% to 7399.39. 

Gainers included plumbing and heating products distributor Ferguson (FERG.LN) , which rose 4.6% as it reported a rise in pretax profit for the fiscal year on 6.1% revenue growth, and said it was outperforming the U.S. market.

AstraZeneca PLC (AZN.LN) slipped 1.7% as it said the U.S. Food and Drug Administration hadn't approved its new drug application for PT010, an inhaled treatment for chronic obstructive pulmonary disease.

 

(END) Dow Jones Newswires

October 01, 2019 06:13 ET (10:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Astrazeneca Charts.